Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 137

Results For "data"

1645 News Found

CanSinoBio’s Convidecia vaccine largely effective against Covid-19 in phase III trial
News | December 24, 2021

CanSinoBio’s Convidecia vaccine largely effective against Covid-19 in phase III trial

The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia


Study shows AstraZeneca’s Covid-19 booster dose protects against Omicron
News | December 23, 2021

Study shows AstraZeneca’s Covid-19 booster dose protects against Omicron

Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant


Evusheld neutralises Omicron in latest studies
News | December 23, 2021

Evusheld neutralises Omicron in latest studies

Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19


World Health Organisation SAGE recommends use of Novavax Covid-19 vaccine as booster
News | December 22, 2021

World Health Organisation SAGE recommends use of Novavax Covid-19 vaccine as booster

SAGE recommends additional third dose of the vaccine administered to immunocompromised persons


Merck acquires Chord Therapeutics to expand its neuroinflammatory pipeline
News | December 22, 2021

Merck acquires Chord Therapeutics to expand its neuroinflammatory pipeline

Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)


CDSCO increases shelf life of Covaxin
Drug Approval | December 21, 2021

CDSCO increases shelf life of Covaxin

The approval of shelf life extension is based on the availability of additional stability data, which was submitted to the CDSCO


NMPA approves CStone's NDA for Cejemly
Drug Approval | December 21, 2021

NMPA approves CStone's NDA for Cejemly

The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients


Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
Biotech | December 21, 2021

Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA

Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers


Salesforce and Azim Premji Foundation launch VaxIT app to speed up Covid-19 vaccination
Public Health | December 21, 2021

Salesforce and Azim Premji Foundation launch VaxIT app to speed up Covid-19 vaccination

The VaxIT app, developed on the Salesforce platform for Azim Premji Foundation and its partners, captures the status of vaccinations to help individuals plan and stay updated on their progress


U.S. FDA approves ANI’s rifabutin capsules, launch soon
Drug Approval | December 21, 2021

U.S. FDA approves ANI’s rifabutin capsules, launch soon

The capsules are the generic version of the reference listed drug Mycobutin